News | July 15, 2022
Syngene signs 10-year biologics manufacturing agreement with Zoetis
Syngene's collaboration with Zoetis started in 2011
Syngene's collaboration with Zoetis started in 2011
This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing.
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
The two-year agreement will grant Lonza access to IBF's prominent network and allow IBF to benefit from Lonza's manufacturing expertise and knowledge in its due diligence review of potential targets
Company will expand the existing production site in Wuxi to significantly increase biopharma single-use assemblies and custom design capabilities
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
In addition, common light chain antibodies generated by RenLite mice can greatly improve the efficiency of downstream assembly of complex drug molecules such as bispecific antibodies and bispecific antibody-drug conjugates (bsADCs)
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.
Subscribe To Our Newsletter & Stay Updated
